Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue-
EPS-$0.15Beat by $0.53
EPS estimate-$0.68

Next report

Aug 4, 2026 (In 6 days)
EPS estimate-$0.71

Financials

Q3 2025

Income statement

See full
Revenue-—
Operating income-$56.9M-2.7%
Net income-$11.2M+83.8%
EPS (diluted)-$0.15+89.0%

Balance sheet

See full
Cash & equivalents$64.9M-9.3%
Total equity$455.1M+39.0%
Total assets$504.6M+19.8%

Cash flow

See full
Operating cash flow-$37.1M-26.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.01B-32.4%

Returns & leverage

See full
Return on equity-38.1%—
Current ratio10.9×+3.6×

Segments

By segment

See full
Reportable Segment-—

Versus estimates

Revenue

Q4 2025$90.5MMiss by $52.4M

Diluted EPS

Q1 2026-$0.74Miss by $0.08Q4 2025-$0.70Miss by $0.04
Q3 2025-$0.15Beat by $0.53
Q2 2025-$0.49Beat by $0.24Q1 2025-$0.74Beat by $0.02Q4 2024-$0.81Beat by $0.08

Ask the moment Spyre Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Spyre Therapeutics, Inc. report Q3 2025 earnings?
Spyre Therapeutics, Inc. (SYRE) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Spyre Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Spyre Therapeutics, Inc. reported revenue of - and eps of $-0.15 for Q3 2025.
Did Spyre Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.68 by $0.53.
How did Spyre Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 89.0% from $-1.36.
Where can I find Spyre Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001636282-25-000104) and the 10-Q periodic report (0001636282-25-000102) directly on SEC EDGAR. The filing index links above go to sec.gov.